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Abstract
Chronic infections and infestations represent major causes of cancer. Overall, Helicobacter pylori, HPV, HBV, and HCV are esti-
mated to account for 15% of all human cancers. We have estimated that cancers associated with 6 pathogens in Italy account
for 31,000 yearly cases, 42.0% of which is attributable to H. pylori, 34.7% to HBV and HCV, 19.8% to HPV, 2.9% to KSHV, and
0.2% to EBV. These figures represent 8.5% of all incident cases of cancer in Italy.
The implementation of anti-HBV vaccination programs in countries with high endemicity resulted in a significant impact on the
incidence of hepatocellular carcinoma, and the availability of antiviral drugs is a real opportunity to drastically reduce the cases
attributable to HCV.
Primary prevention of cervical cancer mainly involves HPV vaccination; two vaccines (bivalent and quadrivalent) are available and
a new vaccine (9-valent) has recently been approved by the FDA. Secondary prevention is based on screening programs that in-
clude Pap smear cytology and/or HPV test.
To reduce the burden of HIV-associated cancers, prevention programs include primary prevention of HIV infection, early diag-
nosis and treatment, restoration of immune function, reduction in the prevalence of associated infections and risk factors, and
secondary prevention.
To date, anti-HBV and anti-HPV vaccinations, eradication of H. pylori infection, treatment of HCV and HIV carriers with antivirals,
and HPV-related cancer screening prove to be the most effective strategies for the prevention of infection-associated cancers.
(Epidemiol Prev 2015; 39(4) Suppl 1: 14-20)
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Riassunto
Le infezioni e infestazioni croniche sono associate con una proporzione rilevante dei tumori umani. Helicobacter pylori, HPV, HBV
e HCV sono complessivamente responsabili del 15% dei tumori nel mondo. In Italia, abbiamo stimato che i tumori associati con 6
agenti patogeni incidano per 31.000 casi all’anno, il 42,0% dei quali è attribuibile a H. pylori, il 34,7% a HBV e HCV, il 19,8% a
HPV, il 2,9% a KSHV e lo 0,2% a EBV. Nel complesso, questi valori rappresentano l’8,5% di tutti i casi incidenti di tumore in Italia.
L’applicazione della vaccinazione anti-HBV in Paesi a elevata endemia ha determinato un notevole impatto anche sul carcinoma
epatocellulare primitivo e la disponibilità di farmaci antivirali rappresenta una concreta possibilità di ridurre l’incidenza di que-
sto tumore, specie quello attribuibile ad HCV.
La prevenzione primaria del carcinoma cervicale si basa principalmente sulla vaccinazione anti-HPV mediante due vaccini (biva-
lente e quadrivalente); recentemente, l’FDA ha approvato un nuovo vaccino (nove-valente). La prevenzione secondaria si basa
su programmi di screening che utilizzano Pap-test e HPV-test.
Per ridurre l’incidenza dei tumori HIV-correlati sono stati promossi programmi di prevenzione incentrati sulla prevenzione primaria
dell’infezione da HIV, diagnosi precoce di sieropositività, riduzione della prevalenza di infezioni e fattori di rischio concomitanti
e sulla prevenzione secondaria.
Nel complesso, le vaccinazioni contro HBV e HPV, l’eradicazione dell’infezione da H. pylori, il trattamento con antivirali dei por-
tatori di HCV e HIV e gli screening oncologici per HPV rappresentano oggigiorno le armi più efficaci per la prevenzione dei tu-
mori di origine infettiva.
(Epidemiol Prev 2015; 39(4) Suppl 1: 14-20)
Parole chiave: tumori di origine infettiva, incidenza in italia, virus dell’epatite B e C, papillomavirus umani, virus dell’immunodeficienza umana
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cers of the oral cavity, oropharynx, nasopharynx, and larynx we
used estimates from Globocan 2012.6 For anal and non-car-
dia gastric cancers we applied each cancer’s sex-specific pro-
portion according to Italian cancer registries7 to the estimates
for Italy in 2014.5 For vulvar and vaginal cancers we consid-
ered their relative ratio to cervix uteri according to Italian
cancer registries.5To estimate penile carcinoma we applied its
ratio to all cancer sites but skin according to Italian cancer reg-
istries7 to the estimate of all sites but skin for Italy in 2014.5
To estimate Burkitt’s and MALT lymphomas we applied the
age- and sex-specific incident rates (2000-2012) from SEER to
the Italian population.8
Population attributable fractions (PAFs) for head and neck
squamous cell carcinomas, including oral cavity, oropharyngeal,
nasopharyngeal, and laryngeal carcinomas,9 for HPV-related
cancers, including vaginal, vulvar, and anal carcinomas10 and
penile carcinoma,11 as well as for non-cardia gastric cancer,
MALT, cervical cancer, and Kaposi’s sarcoma4 were estimated
in the world population. The PAF for Burkitt’s lymphoma was
estimated in the US and European populations.4The PAF for
nasopharyngeal carcinoma was estimated in low-incidence
Regions.4 PAFs for malignant neoplasms of the liver were es-
timated in the Italian population.12
The results of our estimates are shown in table 2. Overall, the can-
cers associated with the considered infectious agents account for
more than 31,000 incident cases (almost 18,000 in males and
more than 13,000 in females), 42.0% of which is attributable to
H. pylori, 34.7% to HBV and HCV, 19.8% to HPV, 2.9% to
KSHV, and 0.2% to EBV. These figures represent 8.5% of all in-
cident cases of cancers in Italy (excluding skin carcinomas) dur-
ing the same period, which have been estimated to be 365,000.5
Clearly, these estimates are just tentative, due to the uncertain-
ties in assessing both the incidence of cancer and the PAFs.
GENERAL STRATEGIES AIMED AT PREVENTING
INFECTION-ASSOCIATED CANCERS
In principle, the primary prevention of infection-related can-
cers is more easily affordable than prevention of other types of
cancer: not only will the prevention of an infectious disease re-
sult in the primary prevention of the associated cancer, but even
its therapy, such as eradication of H. pylori infection or use of
anti-HIV, anti-HBV, or anti-HCV drugs, will avoid evolution
towards malignancy.13
As reported below, certain infection-associated cancers provide
paradigmatic examples of primary prevention and oncological
screening.13 Subsequently, after the onset of cancer and its ther-
apy, it is still possible to apply tertiary prevention, for instance
by means of antiangiogenic agents.14
PREVENTION OF HEPATOCELLULAR CARCINOMA
ASSOCIATED WITH HBV AND HCV INFECTIONS
Mechanistic considerations
There are multiple, diversified mechanisms leading to pri-
mary hepatocellular carcinoma (HCC) in chronic HBV carri-
ers. Liver fibrosis followed by cirrhosis occurs in 20-30% of
chronic HBsAg carriers within 20-30 years, and this is a pre-
GLOBAL BURDEN OF INFECTION-ASSOCIATED
CANCERS
Chronic infections and infestations represent major causes of
cancer. In the population of individual countries, the incidence
of cancers attributable to infectious agents, as evaluated in stud-
ies published between 1981 and 2005, varied between 3.6%
and 29.4%.1 In the world population, taking into account the
infections categorized in Group 1 by the International Agency
for Research on Cancer (IARC), the attributable fraction was
estimated to be 15.6% in 1990,2 17.8% in 2002,3 and 16.1%
in 2008.4
There are large geographical differences in the incidence of in-
fection-associated cancers, with 26.3% of cases occurring in
developing countries and 7.7% in developed countries.3These
regional disparities depend on the different endemic burden of
infections and infestations associated with cancer, on the differ-
ent age composition of the populations of the various countries,
as well as on the uneven application of both primary and sec-
ondary prevention strategies.
OVERVIEW OF CHRONIC INFECTIONS
AND INFESTATIONS ASSOCIATED WITH HUMAN
CANCERS
Table 1 provides a list of the pathogenic agents, including
DNA viruses, RNA viruses, bacteria, protozoa, and trema-
todes, that are known or suspected to play a role in the epi-
demiology of human cancers, along with the main associated
cancers. Eleven of these pathogens are classified in IARCGroup
1, three in Group 2A, and four in Group 2B.Three viral or bac-
terial infections share a particularly heavy burden.Helicobacter
pylori was estimated to be responsible for 90% of non-cardia
gastric cancer cases and 5.2%4 or 5.5%3 of all human cancers.
Persistent infection with HPV is associated with virtually
100% of cervical cancer cases and with a variety of other can-
cers in both men and women, thereby accounting for an esti-
mated 4.8%4 or 5.2%3 of all human cancers. Worldwide,
chronic infections with HBV and HCV were estimated to be
associated with 54.4% and 31.1% of hepatocellular carci-
noma cases, respectively.3 These hepatotropic viruses are re-
sponsible for 4.9%3 or 4.7%4 of all human cancers. Thus, col-
lectively, the above chronic infections (H. pylori, HPV, HBV,
and HCV) are associated with approximately 15% of all hu-
man cancers. Other epidemiologically relevant cancers are
those associated with the herpesviruses EBV (0.9%4 or 1.0%3)
and KSHV (0.3%4).
INCIDENCE OF INFECTION-ASSOCIATED
CANCERS IN ITALY
We estimated the incidence of cancers associated with 6 in-
fectious agents, all of them classified as IARC Group 1, in the
general Italian population. We did not estimate HIV-related
cancers in order to avoid the risk of counting the cancers
caused by immunodeficiency together with the cases directly
related to this infection.
The incidence data for malignant neoplasms of the liver, cervix
uteri, and Kaposi’s sarcoma refer to the year 2014.5 For can-
[IARC Group*] Pathogens Main associated human cancers
DNA viruses
papillomaviridae
[1] human papillomaviruses (HPV), alpha types 16, 18, 31, 33, 35, 39, 45, ■ cervical cancer, cancers of the anogenital region, head and neck cancers,
51, 52, 56, 58, and 59 colorectal cancer
[2A] HPV, alpha type 68
[2B] HPV, alpha types 26, 30, 34, 53, 66, 67, 69, 70, 73,82, 85, 97,
and beta types 5 and 8
[3] HPV, alpha types 6 and 11, other beta and gamma types
herpesviridae
[1] Epstein-Barr virus (EBV, HHV4) ■ Burkitt’s lymphoma, sinonasal angiocentric T-cell lymphoma, immunosuppressor-
related non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, nasopharyngeal carcinoma
[1] Kaposi’s sarcoma virus (KSHV, HHV8) ■ Kaposi’s sarcoma, primary effusion lymphoma
polyomaviridae
[3] simian virus 40 (SV40) ■ malignant mesothelioma?
[2A] Merkel cell virus (MCV) ■ Merkel cell carcinoma
[2B] BK virus (BKV) ■ no specific target detected
[2B] JC virus (JCV) ■ no specific target detected
hepadnaviridae
[1] hepatitis B virus (HBV) ■ hepatocellular carcinoma
RNA viruses
flaviviridae
[1] hepatitis C virus (HCV) ■ hepatocellular carcinoma, B-cell non-Hodgkin’s lymphoma
defective virus
[3] hepatitis D virus (HDV)
retroviridae
[1] human T-cell leukemia virus-I (HTLV-I) ■ adult T-cell leukemia-lymphoma
[3] human T-cell leukemia virus-II (HTLV-II)
[1] human immunodeficiency virus-1 (HIV-1) ■ Kaposi’s sarcoma, non-Hodgkin’s lymphoma, Hodgkin’s lymphoma,
cervical cancer, anal cancer, conjunctival cancer
[2B] human immunodeficiency virus-2 (HIV-2)
[NA]human endogenous retrovirus (HERV-K) ■ breast cancer?
[NA]xenotropic murine leukemia virus-related virus (XMRV) ■ prostate cancer?
Bacteria
[1] Helicobacter pylori ■ non-cardia gastric cancer, MALT lymphoma
[NA]Salmonella typhi ■ gallbladder carcinoma?
[NA]Streptococcus bovis ■ colorectal cancer?
[NA]Clamydophila pneumonia ■ lung cancer?
[NA]Mycobacterium tubercolosis ■ lung cancer?
[NA]Bartonella species ■ vascular tumors?
Protozoa
[2A] Plasmodium falciparum ■ Burkitt’s lymphoma (+EBV)
[NA]Trichomonas vaginalis ■ prostate cancer?
Trematodes
[1] Schistosoma haematobium ■ urinary bladder cancer
[2B] Schistosoma japonicum ■ colorectal and liver cancer
[3] Schistosoma mansoni
[1] Opistorchis viverrini ■ cholangiocarcinoma
[3] Opistorchis felineus
[1] Chlonorchis sinensis ■ cholangiocarcinoma
* Group 1: sufficient evidence of carcinogenicity to humans; Group 2A: probably carcinogenic; Group 2 B: possibly carcinogenic; Group 3: inadequate evidence of carcinogenicity to humans; NA: not available.
Table 1. Pathogenic agents and main associated human cancers. / Tabella 1. Agenti patogeni e principali tumori umani associati.
cursor condition for development of 80%-90% of HCC
cases.15HBV-DNA is also able to integrate into the hepatocyte
DNA, and several alterations can occur in the host genome,
such as HBx gene expression, chromosomal deletions, fusion
transcripts, translocations, DNA amplification, and genomic
instability, which independently contribute to HCC develop-
ment.13 Interactions between HBV infection and chemical he-
patocarcinogens are also of crucial importance in the patho-
genesis of HCC.16 On the other hand, HCV lacks reverse
transcriptase activity, and is thus unable to integrate its genome
into the host cell DNA, while viral protein expression has a crit-
ical role in hepatocarcinogenesis by altering signal transduction
pathways;15 this has two important implications:
■ HCV-induced cirrhosis is the necessary mechanism for its
carcinogenesis;
■ due to the lack of DNA integration into the host genome,
antiviral drugs have the potential to achieve a “sterilizing” ef-
fect in chronically infected subjects.17
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Prevention programs
Avoiding viral infection through primary preventionmeasures is
crucial in order to obtain a dramatic decrease inHCC incidence.
Regarding HBV, universal vaccination programs of new-
borns/infants have been introduced in 183 world countries,
with 81% coverage overall with 3 doses.18 There is clear evi-
dence on the impact of immunization on HCC in countries
where such programs have been implemented for a long time,
as was first demonstrated in cohorts of Taiwanese children aged
6-14 years19 and, later, in adolescents aged 16-19 years.20
Similar results are reported fromThailand, China, Singapore,
Korea, Japan, and Alaska, and are expected to be available from
Gambia in the coming years.21
No vaccine is presently available for HCV due to the high vari-
ability of envelope proteins. Primary prevention of HCV in-
fection is based upon identification of infectious blood donors
through anti-HCV detection and NAT (nucleic acid testing),
careful application of universal precautions for blood-borne in-
fections, and adequate sterilization of non-disposable medical
equipment. Of course, the same measures represent an im-
portant complement to hepatitis B vaccination for the pre-
vention of HBV-related HCC.
With regard to HCC secondary prevention, data on the impact
of IFN (interferon) therapy for HBV-related cancers are con-
flicting, due to the lack of pre-treatment patient stratification for
relevant cancer predictors and exclusion of patients at higher risk
of developing HCC, such as those unfit to receive IFN owing
to advanced hepatitis. The advent of user-friendly oral NUC
(nucleoside/nucleotide analogs) allowed for a broader and safe
access of patients to effective anti-HBV therapy. HCC was pre-
vented in patients with chronic hepatitis but not in those with
cirrhosis, and in general in patients that could not achieve com-
plete virological suppression. The re-analysis of outcomes fol-
lowing patient stratification for risk factors of HCC helped
shed light on an association between NUC therapy and a re-
duced HCC risk only in non-cirrhotic patients.22
As regards to HCV antiviral therapy, a meta-analysis of 30 ob-
servational studies of patients treated with interferon demon-
strated a more than 70% reduction of HCC risk occurring in-
dependently of severity of the underlying liver fibrosis. The
residual risk for HCC in SVR (sustained virologic response) pa-
tients might reflect persistence of cirrhosis following virus steril-
ization. The same factors predicting HCC in viremic patients,
such as advanced age, portal hypertension, advanced fibrosis, and
elevated alpha-fetoprotein levels, act as independent predictors of
HCC in SVR patients, too. This further emphasizes the clinical
advantages of treating patients early during infection.22 IFN-free,
DAA (direct acting antiviral)-based regimens, such as sofosbuvir
+ ribavirin with a 24-week course, can also eliminate HCV in-
fection in two-thirds of patients awaiting liver transplantation or
already transplanted, with obvious positive consequences on
their short- and long-term prognoses (tertiary prevention).23
PREVENTION OF HPV-ASSOCIATED CANCERS
Foreword
Worldwide epidemiological studies indicate that 12 different
high-risk HPVs, namely 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, and 59, are associated with cervical cancer; they are there-
fore classified in IARC Group 1 (table 1).
A subset of anal, penile, vulvar, vaginal, and oropharyngeal can-
cers have been attributed to infection with high-risk HPVs,
mainly to HPV 16.24 Prevention of cervical cancer includes
both primary prevention, through HPV vaccination and ed-
ucation about safe sexual practices, and secondary prevention
through cervical cancer screening.
Primary prevention
Two vaccines (bivalent and quadrivalent) are available to pro-
tect against HPV types 16 and 18, which are responsible for
approximately 50% and 20% of cervical cancers, respectively.
In addition, the quadrivalent vaccine offers protection against
HPV 6 and 11, which cause over 90% of genital warts. Vac-
cination programs are being widely implemented, primarily
targeting adolescent girls, and efficacy has been widely demon-
strated for both vaccines by showing a 93%-100% of vaccine
efficacy in preventing cervical pre-cancers due to HPV 16 or
18. Millions of doses have been distributed worldwide so far,
and all randomized controlled clinical trials of both vaccines
provide evidence for an excellent safety profile.25,26 In some
Italian Regions, vaccination programs have recently been ex-
tended to 12-year old boys, as recommended by the 2014 life-
time immunization schedule approved by the Italian scientific so-
cieties.27 Although this strategy is still debated, recent evidence
shows a trend toward better results in cost-effectiveness of
universal vaccination versus girls-only vaccination.28,29
The convenience of extending the anti-HPV vaccination to
males is also supported by the estimates reported in the pres-
ent study. As inferred from the data available in table 2, HPV-
related cancers in males appear to account for 38% of all the
cases estimated in the Italian population. With regard to the
issue of extending the HPV vaccination recommendation to
older women, an economic modeling study regarding 330,000
25-year old women in Italy showed that immunization with
the HPV vaccine is fully economically justified, with an ICER
(incremental cost-effectiveness ratio) =€ 33,918/QALY (qual-
ity adjusted life years) using the vaccine prices of 2011 (prices
have gone down since then). The same analysis showed that a
public health program of HPV vaccination would be justified
(ICER < € 50,000/QALY) until 30 years without cross-pro-
tective effects of the vaccine, and up to 35 years considering
cross-protection.30Moreover, a new vaccine (9-valent) has re-
cently been approved by the FDA. It is indicated in girls and
women 9 through 26 years of age for the prevention of cervi-
cal, vulvar, vaginal, and anal cancer caused by HPV types 6, 11,
16, 18, 31, 33, 45, 52, and 58.31
Secondary prevention
Secondary prevention involves screening asymptomatic patients
or carrying out definitive tests in symptomatic or screen-positive
patients to pick up precancerous lesions before they turn into
cancer. Observational studies have shown that introduction of
any regular cervical cancer screening program results in a drop
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in the incidence of invasive cervical cancer and cancer deaths.
Different methods are available for cervical cancer screening:
cervical cytology (Pap test) is the globally preferred screening
method and has been shown to reduce the incidence of inva-
sive cervical cancer by up to 80%.
Two types of tests for HPV DNA are currently in use; one is
a nucleic acid hybridization assay with signal amplification for
the qualitative detection of high risk HPV types in cervical
specimens, whereas the other is a polymerase chain reaction
based assay. Testing for HR (high risk)-HPV has been investi-
gated as a primary screening test in several randomized clini-
cal trials. Cross-sectional as well as longitudinal studies have
consistently demonstrated the superiority of HPV testing,
compared with Pap testing, to prevent invasive cervical cancer
by detecting high-grade precancerous lesions. However, HPV
testing is also associated with a lower specificity, especially in
younger women.32
By 2018, screening programs in Italy will rely more on HPV
testing than cytology, with the following schedule: at 25-30/35
years Pap smear as a primary test and triage ASCUS (squamous
cells of undetermined significance) with HPV test every 3
years; at >30/35 years HPV test as a primary test and triage with
Pap smear every 5 years. Moreover, HPV testing will be the ap-
proach to follow up women treated for CIN-2 (cervical in-
traepithelial neoplasia-2) and with cytological abnormalities and
negative colposcopy.The 5-year interval will lead to cost savings,
and using the HPV test as the primary test will be key to im-
proving uptake of cervical screening programs.33
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Cancer site or morphology ICD 10 Infectious PAF Sex Estimated Estimated
agent (%) annual incident incidence attributable
cases to infectious agents
oral cavity C00-C08 HPV 23.5 M 2,283 537
W 1,524 358
P 3,807 895
oropharyngeal C09-C10, C12-C14 HPV 35.6 M 1,214 432
(including hypo pharynx and pharynx) W 348 124
P 1,589 566
nasopharyngeal C11 EBV 80.0 M 315 252
W 124 99
P 439 351
laryngeal C32 HPV 24.0 M 3,714 891
W 335 80
P 4,049 972
Burkitt’s lymphoma C83.7 EBV + 20.0 M 200 40
Plasmodium W 100 20
falciparum P 300 60
non-cardia gastric cancer C16.1-C16.9 Helicobacter 90.0 M 7,500 6,750
pylori W 5,500 4,950
P 13,000 11,700
MALT (stomach) C88.4 Helicobacter 86.0 M 700 602
pylori W 850 731
P 1,550 1,333
malignant neoplasms of liver C22 HBV, HCV 86.8 M 8,600 7,465
W 3,800 3,298
P 12,400 10,763
anal carcinoma C21.0 HPV 84.3 M 450 379
W 650 548
P 1,100 927
penile carcinoma C60 HPV 46.9 M 182 85
uterine cervix cancer C53 HPV 100 W 2,200 2,200
vulvar cancer C51 HPV 40.4 W 900 364
vaginal cancer C52 HPV 60.9 W 200 122
Kaposi’s sarcoma C46 HHV8 100 M 600 600
W 300 300
P 900 900
all the above tumors M 25,758 18,034
W 16,831 13,194
P 42,589 31,238
Table 2. Estimated number of cancers attributable to 6 infectious agents in Italy. Cancer site, International classification for diseases-10 (ICD-10) codes, infectious agent,
population-attributable fraction (PAF), estimated annual number of incident cases and estimated number of cases attributable to infectious diseases, by sex (M: men,W:
women, P: people).
Tabella 2. Stima del numero di tumori attribuibili a 6 agenti infettanti in Italia. Sede del cancro, codici dell’International classification for diseases-10 (ICD-10), agenti
infettanti, frazione attribuibile alla popolazione (PAF), numero annuale stimato di casi incidenti attribuibile a malattie infettive, distinto per sesso (M: uomini,W: donne,
P: uomini + donne).
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PREVENTION OF CANCERS ASSOCIATED
WITH HIV INFECTION
Foreword
The association between HIV/AIDS and cancer is still unclear,
although HIV is classified as a Group 1 IARC carcinogen34 and
several authors have associated an increased cancer risk with
HIV-related immunodeficiency, chronic immune activa-
tion/inflammation, and immune dysfunction/senescence.35
Epidemiological evidence suggests that the increased cancer risk
observed among HIV-infected patients could be, at least in
part, attributed to co-infection with other cancer-related
viruses, such as KSHV, EBV, HPV, HBV, and HCV, and to a
higher exposure to lifestyle risk factors for cancer, including
smoking and alcohol use.35,36 Furthermore, the use of highly
active antiretroviral therapy (HAART) has dramatically im-
proved survival, and most HIV-infected patients live several
decades after their diagnosis.
In most developed countries, effective treatment of HIV has
contributed to increase the prevalence of HIV infection,
thereby leading to a higher clinical impact of long-term mor-
bidities, including cancers.37 For instance, in Italy people liv-
ing with HIV increased from 78,000 in 1990 to 120,000 in
2013 (http://www.who.int/gho/hiv/en/).
Prevention programs
Research programs aimed at understanding, preventing, and
treating HIV-related cancers have been promoted.38 These
programs are based on the following five pillars:
■ Primary prevention of HIV infection. Preventing HIV in-
fection or, at least, limiting the number of HIV-infected cells
and viral load would greatly contribute to the reduction of
associated cancers.39 For this reason, the development of ef-
fective vaccines against HIV may be one of the biggest chal-
lenges for medical science. Unfortunately, to date, no fully
effective HIV vaccine is available and prevention strategies
should therefore be based on the promotion of counselling
for HIV testing in high-risk populations and implementa-
tion of behavioural measures aimed at controlling HIV
transmission via sexual intercourse, blood and other body
fluids, and perinatal exposure of fetuses and children.13
■ Early diagnosis and treatment of HIV infection, and
restoration of immune function. Early diagnosis of HIV in-
fection, linkage to and retention in care, and adherence to
antiretroviral therapy are crucial in reducing the cancer bur-
den in HIV-infected subjects.40 In addition, evidence from
in vitro and in vivo model systems indicates that antiretro-
viral agents may have antitumor activity independent of
their antiviral effect.41
■ Reduction in the prevalence of non-communicable risk fac-
tors. A number of cancers observed among HIV subjects are
attributable to exposure to tobacco smoking (e.g., cancers of
the lung, head and neck, bladder), alcohol consumption
(e.g., cancers of liver and head and neck) and ultraviolet ra-
diation (non-melanoma skin cancer).42 Accordingly, pro-
grams to encourage HIV-infected individuals to quit tobacco
smoking and alcohol consumption and minimize unneces-
sary sun exposure should be a priority for public health
authorities.
■ Primary prevention of concomitant cancer-related viral
infections. As previously discussed, prevention of chronic in-
fections with other cancer-related viruses, such as HBV and
HPV infections, should be optimized. Cancers caused by
EBV and KSHV may be in principle preventable with vac-
cines, with early candidate vaccines for EBV showing prom-
ise.43 Finally, encouraging HIV-infected people to limit the
number of their sexual partners may reduce their risk of ac-
quiring new HBV and HPV infections.
■ Secondary prevention. Limited data exist regarding harms
and benefits of cancer screening interventions specifically tar-
geted to HIV-infected persons. For some cancers, perform-
ance of screening programs may be sufficiently different in
HIV-infected individuals to warrant modified approaches.
Thus, cancer screening interventions that have no evidence
of benefit in the general population (e.g., anal, skin, and liver
cancer screening42) may be of value in HIV-infected indi-
viduals because of their different cancer risk profiles. How-
ever, the decision to screen HIV-infected persons for cancer
is complex and should include considerations about the risk
of the particular cancer, the life expectancy of the patient,
and the specific benefits and harms that may stem from the
screening interventions.44
CONCLUSIONS
A high proportion of cancers are associated, with a variety of
mechanisms, with chronic infections and infestations. In Italy,
cancers associated with the 6 main pathogens appear to be re-
sponsible for almost 1 out of 10 cancers, with a total of 31,000
yearly cases, the large majority of which are attributable to
either H. pylori (42.0%), HBV and HCV (34.7%), or HPV
(19.8%).
The major strategies for the prevention of these cancers involve
a variety of measures, including large-scale vaccinations against
HBV and HPV, eradication of H. pylori infection, treatment
of HCV-positive and HIV-positive subjects in order to avoid
chronic infections, control of both concomitant infections
and exposure to synergistically-acting lifestyle and environ-
mental risk factors, and secondary prevention of the associated
cancers, with special emphasis on cancer screening for HPV.
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